A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
This study aims to test the feasibility, acceptability, and preliminary efficacy of a comprehensive self-management (CSM) intervention for people with inflammatory bowel disease (IBD). The CSM-IBD intervention is an adaption of the CSM intervention initially developed for individuals with irritable bowel syndrome. The intervention has eight sessions which cover an introduction to IBD, symptom tracking, cognitive behavioral strategies, relaxation, sleep, diet, and pain management.
|Condition or Disease||Intervention/Treatment||Phase|
Arms and Interventions
|Experimental: Comprehensive Self-Management
The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.
Behavioral: Comprehensive Self-Management Intervention
In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
|Other: Usual care group
The control group will receive standard care without the comprehensive self-management intervention.
The control group will receive standard care.
Primary Outcome Measures
- Recruitment feasibility [From screening to enrollment]
Percentage comprised of number of participants enrolled divided by the number of participants approached.
- Intervention feasibility [3 months]
Measured with the Feasibility of Intervention Measure (FIM) in which participants respond to four questions on a 5-point Likert scale from completely disagree (1) to completely agree (5).
- Acceptability [6 months]
A semi-structured interview guide will be used to assess acceptability of study procedures as well as acceptability and satisfaction with the intervention.
Secondary Outcome Measures
- Change in Quality of Life [Baseline, 3 months, 6 months]
Short Inflammatory Bowel Disease Questionnaire is a 10-item questionnaire which evaluates quality of life. Participants respond on a 7-item Likert scale from all the time to none of the time. Total score range: 10 to 70.
- Change in Symptoms [Baseline, 3 months, 6 months]
Symptoms are measured using a numeric rating scale where participants report the severity of the symptom from not present (0) to worst possible (10). Symptoms include: abdominal pain, anxiety, bloating, constipation, depressed, diarrhea, fatigue/tiredness, passing gas, sleepiness during the day, stress, and urgency.
Other Outcome Measures
- Self-Efficacy for Managing Chronic Disease [Baseline, 3 months, 6 months]
a 6-item self-report scale. Participants report ranging from not at all confident to totally confident.
- Index of Self-Regulation [Baseline, 3 months, 6 months]
a 9-item scale to measure individual's level of self-regulation
- Patient Activation Measure [Baseline, 3 months, 6 months]
a 13-item scale which assess patient's beliefs, knowledge and confidence in managing their health
- Fecal Calprotectin [Baseline, 3 months]
Level of fecal calprotectin assessed using ELISA.
- Gut Microbiome [Baseline, 3 months]
Fecal microbial communities characterized using 16S rRNA gene sequencing on the Illumina MiniSeq platform (Illumina, Inc. Albany, New York)
Healthcare provider diagnosis of inflammatory bowel disease
Report current symptoms
Able to read and write in English
Live outside of Washington state
Bowel-related surgery within the past month
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- University of Washington
- National Institute of Nursing Research (NINR)
- Principal Investigator: Kendra Kamp, PHD, RN, University of Washington
Study Documents (Full-Text)None provided.